Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 389-398

  Pierce, Lori J ^a   Phillips, Kelly Anne ^b   Griffith, Kent A ^c   Buys, Saundra ^d   Gaffney, David K ^d   Moran, Meena S ^e   Haffty, Bruce G ^f   Ben David, Merav ^g   Kaufman, Bella ^g   Garber, Judy E ^h   Merajver, Sofia D ^a   Balmaña, Judith ⁱ   Meirovitz, Amichay ^j   Domchek, Susan M ^k  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g TEL AVIV UNIVERSITY   (Israel)

^h HARVARD UNIVERSITY   (United States)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

BRCA1 2; Breast conservation; Hereditary breast cancer; Mastectomy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTECTOMY; OVARIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 77953028921     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0894-z     Document Type: Article

References (26)

1. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCAl and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408 (Pubitemid 27208598)
2. Begg CB, Haile R, Borg A et al (2008) Variation of breast cancer risk amond BRCAl/2 carriers. JAMA 299: 194-201
3. Fisher B, Anderson. S, Bryant J et al (2002) Twenty-year followup of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233-1241. (Pubitemid 35176242)
4. Veronesi U, Cascinelli. N, Mariani. L et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347: 1227-1232 (Pubitemid 35176241)
5. Mann GJ, Thorne H, Balleine RM et al (2006) Analysis of cancer risk and BRCAl and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8: R12
6. Phillips KA, Milne RL, Buys S et al (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based breast cancer family registry. J Clin Oncol 23: 4679-4686 (Pubitemid 46224070)
7. Kaplan. EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53457-53481
8. Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 18: 695-706 (Pubitemid 29126745)
9. Pepe M (1991.) Inference for events with dependent risks in multiple endpoints studies. J Am. Stat Assoc 86: 770-778
10. Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366: 2087-2106
11. Schwartz GF, Veronesi U, Clough KB, et al (2006) In: Proceedings on the consensus conference on breast conservation, April 28 to May 2, 2005, Milan, Italy. Cancer 107: 242-250
12. Turner BC, Harrold E, Matloff E et al (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breastconserving management in patients with BRCAI/BRCA2 mutations. J Clin Oncol 17: 3017-3024 (Pubitemid 29470628)
13. Donegan WL, Perez-Mesa CM, Watson FR (1966) A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 122: 529-540
14. Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of nodenegative breast cancer. J Clin Oncol 27: 2466-2473
15. Wapnir IL, Anderson SJ, Mamounas EP et al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24: 2028-2037
16. Fourquet A, Stoppa-Lyonnet D, Kirova YM et al (2009) Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 32: 127-131
17. Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCAl- and BRCA2-associated breast and gynecologic cancer: a multicenter prospective study. J Clin Oncol 26: 1331-1337
18. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCAl and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251-2256 (Pubitemid 33063147)
19. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718-1729 (Pubitemid 26134232)
20. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24: 2437-2443
21. Verhoog LC, Brekelmans CTM, Seynaeve C et al (1998) Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351: 316-321 (Pubitemid 28052696)
22. Eccles D, Simmonds P, Goddard J et al (2001) Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer 1: 65-72 (Pubitemid 35221517)
23. Robson M, Levin D, Federici M et al (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91: 2112-2117 (Pubitemid 30019573)
24. Haffty B, Harold E, Khan A et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359: 1471-1477 (Pubitemid 34457765)
25. Kirova YM, Stoppa-Lyonnet D, Savignoni A et al (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breastconserving surgery and radiotherapy. Eur J Cancer 41: 2304-2311 (Pubitemid 41415607)
26. Garcia-Etienne C, Barile M, Gentilini O, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: Are we approaching an answer? Ann Surg Oncol, doi 10.1245/s 10434-009-0638-647